Expertise in
6
conditions

Tawesak Tanwandee

Bangkok, TH 
Expertise in
6
conditions
Bangkok, TH 
OverviewLocationsClinical Research

Overview

Tawesak Tanwandee practices in Bangkok, Thailand. Tanwandee is highly rated in 6 conditions, according to our data. Their top areas of expertise are Hepatitis B, Hepatitis, Liver Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Transplant.

Their clinical research consists of co-authoring 100 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Bangkok, Thailand
Other Locations
Salaya, Thailand
Nakhon Pathom, Thailand
Thailand
Bangkok Noi, Thailand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm
Enrollment Status: Completed
Publish Date: August 20, 2024
Intervention Type: Drug
Study Phase: Phase 3
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Other
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital
The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital
Enrollment Status: Completed
Publish Date: March 23, 2017
Intervention Type: Other
View 3 Less Clinical Trials

100 Total Publications

Liver disease trends in the Asia-Pacific region for the next 50 years.
Liver disease trends in the Asia-Pacific region for the next 50 years.
Journal: Clinical and molecular hepatology
Published: January 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tanwandee's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile